<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081819</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2015_SH003</org_study_id>
    <nct_id>NCT03081819</nct_id>
  </id_info>
  <brief_title>A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer</brief_title>
  <official_title>A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer.

      The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one
      in six participants, the dose is escalated.

      The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than
      one in six participants, the dose is escalated.

      The third dose group receives SH003 for 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <description>Grade 3-4 adverse event using CTCAE v4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>SH003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take SH003 for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH003</intervention_name>
    <description>Herbal medicine for cancer treatment</description>
    <arm_group_label>SH003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years or older

          -  Patients with histologically and cytologically confirmed solid tumor

          -  Patients who have failed standard treatments, such as previous chemotherapy or
             radiotherapy, or who are inoperable, refractory, or progressive.

          -  ECOG score 0-2

          -  Patients with a minimum life expectancy of 12 weeks at the scheduled starting date of
             the study drug

          -  Previous treatment with surgery or radiotherapy, at least 4 weeks since end of
             treatment is allowed (the patient should have been recovered from any side effects.

          -  Patients who can swallow pills.

          -  Patients who provide written informed consent for participation in the trial

        Exclusion Criteria:

          -  Known hypersensitivity to any study drug component, including Astragalus membranaceus,
             Angelica gigas, or Trichosanthes Kirilowii Maximowicz

          -  Patients with pre-existing cardiac conditions:

          -  Prior documented myocardial infarction within the last 6 months

          -  Pre-existing cardiac failure (NYHA class III-IV)

          -  Atrial fibrillation on anti-coagulants

          -  Unstable angina

          -  Severe valvulopathy

          -  Cardiac angioplasty or stenting with in the last 6 months

          -  Pregnant or lactating females

          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety

          -  Active uncontrolled infection, including known history of AIDS or hepatitis B or C

          -  Any psychological, sociological, or geographical condition that could potentially
             interfere with compliance with the study protocol

          -  Concurrently receiving any other investigational agents while on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunhoo Cheon, Doctor</last_name>
    <phone>82-2-961-9278</phone>
    <email>hreedom35@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EUNJIN KWON</last_name>
      <phone>+82-31-219-6324</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Seong-Gyu Ko</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

